No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes.
BACKGROUND Patients with type 2 diabetes are under high oxidative stress , and levels of hyperglycemia correlate strongly with levels of LDL oxidation . Carnitine favorably modulates oxidative stress . OBJECTIVE This objective of this study was to evaluate the efficacy of L-carnitine on the reduction of oxidized LDL cholesterol in patients with type 2 diabetes . DESIGN Eighty-one patients with diabetes were r and omly assigned to 1 of 2 treatment groups for 3 mo . The 2 groups received either 2 g L-carnitine once daily ( n = 41 ) or placebo ( n = 40 ) . The following variables were assessed at baseline , after washout , and at 1 , 2 , and 3 mo of treatment : body mass index , fasting plasma glucose , glycosylated hemoglobin , total cholesterol , LDL cholesterol , HDL cholesterol , triglycerides , apolipoprotein A1 , apolipoprotein B-100 , oxidized LDL cholesterol , thiobarbituric acid-reactive substances , and conjugated dienes . RESULTS At the end of the study period , the L-carnitine-treated patients showed significant improvements compared with the placebo group in the following markers : oxidized LDL levels decreased by 15.1 compared with 3.0 U/L ( P < 0.001 ) ; LDL cholesterol decreased by 0.45 compared with 0.16 mmol/L ( P < 0.05 ) ; triglycerides decreased by 1.02 compared with 0.09 mmol/L ( P < 0.001 ) ; apolipoprotein A1 concentrations decreased by 0.12 compared with 0.03 mg/dL ( P < 0.05 ) ; apolipoprotein B-100 concentrations decreased by 0.13 compared with 0.04 mg/dL ( P < 0.05 ) ; thiobarbituric acid-reactive substance concentrations decreased by 1.92 compared with 0.05 ( P < 0.001 ) , and conjugated diene concentrations decreased by 0.72 compared with 0.11 in the placebo group ( P < 0.001 ) . CONCLUSION Our study indicates that oral administration of L-carnitine reduces oxidized LDL cholesterol levels in patients with type 2 diabetes
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .